|
Compound was evaluated for cell growth inhibition against HL 60 cell line by irradiation in the presence of examined compound
|
Homo sapiens
|
750.0
nM
|
|
|
The IC50-UVA is the dose of UVA light which in the presence of fixed drug concentration (20 uM) is necessary to induce a 50% inhibition of DNA synthesis by incubation at the ground state by keeping mammalian cells in the dark.
|
None
|
3.59
kJ m**-2
|
|
|
The IC50-UVA is the dose of UVA light which in the presence of fixed drug concentration (20 uM) is necessary to induce a 50% inhibition of clonal growth by incubation at the ground state by keeping mammalian cells in the dark
|
None
|
1.23
kJ m**-2
|
|
|
In vivo inhibition of epidermal DNA synthesis in mouse after oral administration
|
Mus musculus
|
39.1
%
|
|
|
In vivo inhibition of epidermal DNA synthesis in mouse after topical application
|
Mus musculus
|
61.0
%
|
|
|
Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 3.2 joule/cm**2 UVA dose
|
Homo sapiens
|
700.0
nM
|
|
|
Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 6.5 joule/cm**2 UVA dose
|
Homo sapiens
|
400.0
nM
|
|
|
Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-aminoanthracene-induced mutation at 600 ug/plate after 72 hrs in presence of Ames S-9 fraction
|
Salmonella enterica subsp. enterica serovar Typhimurium
|
44.0
%
|
|
|
Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-aminoanthracene-induced mutation at 300 ug/plate after 72 hrs in presence of Ames S-9 fraction
|
Salmonella enterica subsp. enterica serovar Typhimurium
|
0.0
%
|
|
|
Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-aminoanthracene-induced mutation at 150 ug/plate after 72 hrs in presence of Ames S-9 fraction
|
Salmonella enterica subsp. enterica serovar Typhimurium
|
0.0
%
|
|
|
Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of acetylaminofluorene-induced mutation at 600 ug/plate after 72 hrs in presence of Ames S-9 fraction
|
Salmonella enterica subsp. enterica serovar Typhimurium
|
39.0
%
|
|
|
Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of acetylaminofluorene-induced mutation at 300 ug/plate after 72 hrs in presence of Ames S-9 fraction
|
Salmonella enterica subsp. enterica serovar Typhimurium
|
21.0
%
|
|
|
Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of acetylaminofluorene-induced mutation at 150 ug/plate after 72 hrs in presence of Ames S-9 fraction
|
Salmonella enterica subsp. enterica serovar Typhimurium
|
0.0
%
|
|
|
Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of benzo[a]pyrene-induced mutation at 600 ug/plate after 72 hrs in presence of Ames S-9 fraction
|
Salmonella enterica subsp. enterica serovar Typhimurium
|
86.0
%
|
|
|
Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of benzo[a]pyrene-induced mutation at 300 ug/plate after 72 hrs in presence of Ames S-9 fraction
|
Salmonella enterica subsp. enterica serovar Typhimurium
|
76.0
%
|
|
|
Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of benzo[a]pyrene-induced mutation at 150 ug/plate after 72 hrs in presence of Ames S-9 fraction
|
Salmonella enterica subsp. enterica serovar Typhimurium
|
58.0
%
|
|
|
Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-nitroflorene-induced mutation at 600 ug/plate after 72 hrs
|
Salmonella enterica subsp. enterica serovar Typhimurium
|
25.0
%
|
|
|
Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-nitroflorene-induced mutation at 300 ug/plate after 72 hrs
|
Salmonella enterica subsp. enterica serovar Typhimurium
|
39.0
%
|
|
|
Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-nitroflorene-induced mutation at 150 ug/plate after 72 hrs
|
Salmonella enterica subsp. enterica serovar Typhimurium
|
5.0
%
|
|
|
Inhibition of TPA-induced EBV-early antigen activation in human Raji cells
|
Human herpesvirus 4
|
490.0
molar ratio
|
|
|
Photocytotoxicity against human LoVo cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
|
Homo sapiens
|
700.0
nM
|
|
|
Photocytotoxicity against human NCTC 2544 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
|
Homo sapiens
|
900.0
nM
|
|
|
Phototoxicity against human LoVo cells exposed to irradiation with 3.75 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay
|
Homo sapiens
|
700.0
nM
|
|
|
Antitumor activity against human HeLa cells after 72 hrs by MTS assay
|
Homo sapiens
|
7.6
ug.mL-1
|
|
|
Mechanism based inhibition of human cytochrome P450 2A6 measured by coumarin 7-hydroxylation using a recombinant system
|
Homo sapiens
|
800.0
nM
|
|
|
DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)
|
None
|
40.0
nM
|
|
|
Inhibition of recombinant human BACE1 using Rh-EVNLDAEFK as substrate at 500 uM after 60 mins by fluorescence quenching assay
|
Homo sapiens
|
-4.9
%
|
|
|
Inhibition of electric eel AChE at 2 mg/ml by Ellman's method
|
Electrophorus electricus
|
4.4
%
|
|
|
Inhibition of horse BChE at 2 mg/ml by Ellman's method
|
Equus caballus
|
8.34
%
|
|
|
Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting
|
Homo sapiens
|
38.1
%
|
|
|
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting
|
Homo sapiens
|
8.9
%
|
|
|
Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting
|
Homo sapiens
|
-1.6
%
|
|
|
Antioxidant activity assessed as inhibition of AAPH-induced linoleic acid lipid peroxidation at 100 uM by spectrophotometric analysis
|
None
|
5.0
%
|
|
|
Inhibition of acetylcholinesterase (unknown origin) using acetylcholine iodide as substrate preincubated for 15 mins prior to substrate addition by spectrophotometric analysis
|
Homo sapiens
|
760.0
nM
|
|
|
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM
|
Cricetulus griseus
|
102.46
%
|
|
|
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM
|
Cricetulus griseus
|
107.28
%
|
|
|
Inhibition of PTP1B (unknown origin) at 20 ug/ml using pNPP substrate measured after 3 mins by colorimetric assay
|
Homo sapiens
|
50.0
%
|
|
|
Mixed inhibition of CYP2A13 (unknown origin)
|
Homo sapiens
|
40.0
nM
|
|
|
Mixed inhibition of CYP2A6 (unknown origin)
|
Homo sapiens
|
250.0
nM
|
|
|
Anti-proliferative activity against human L02 cells after 48 hrs by MTT assay
|
Homo sapiens
|
3.3
%
|
|
|
Inhibition of recombinant human CYP1A1 expressed in baker's yeast-derived microsomes (Sacchrosomes) at 10 uM using 7-ethoxyresorufin substrate by EROD assay relative to control
|
Homo sapiens
|
84.0
%
|
|
|
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600)
|
Staphylococcus aureus subsp. aureus
|
13.34
%
|
|
|
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600)
|
Escherichia coli
|
-6.11
%
|
|
|
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600)
|
Klebsiella pneumoniae
|
4.76
%
|
|
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600)
|
Klebsiella pneumoniae
|
9.19
%
|
|
|
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600)
|
Pseudomonas aeruginosa
|
12.61
%
|
|
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600)
|
Pseudomonas aeruginosa
|
9.57
%
|
|
|
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by OD600
|
Acinetobacter baumannii
|
12.68
%
|
|
|
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630
|
Candida albicans
|
-3.39
%
|
|
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630
|
Candida albicans
|
5.22
%
|
|
|
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570)
|
Cryptococcus neoformans
|
-9.6
%
|
|
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570)
|
Cryptococcus neoformans
|
-0.09
%
|
|
|
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media using NBS plates, by Resazurin F(560/590)
|
Staphylococcus aureus subsp. aureus
|
3.08
%
|
|
|
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by Resazurin F(560/590)
|
Acinetobacter baumannii
|
-6.09
%
|
|
|
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by Resazurin F(560/590)
|
Escherichia coli
|
2.12
%
|
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging
|
Homo sapiens
|
5.62
%
|
|
|
Phototoxicity against mouse PAM212 cells assessed as cell growth inhibition preincubated for 30 mins followed by 1.28 J/cm2 UV light exposure and measured after 5 days by coulter counting method
|
Mus musculus
|
100.0
nM
|
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
14.31
%
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
15.15
%
|
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.12
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.42
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.42
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.12
%
|
|
